Published in Expert Rev Anticancer Ther on January 01, 2007
Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer (2014) 0.98
pH-triggered conformational switching along the membrane insertion pathway of the diphtheria toxin T-domain. Toxins (Basel) (2013) 0.93
Sensitivity of cancer cells to truncated diphtheria toxin. PLoS One (2010) 0.86
A mathematical model for the rational design of chimeric ligands in selective drug therapies. CPT Pharmacometrics Syst Pharmacol (2013) 0.83
Manipulation of regulatory T cells and antigen-specific cytotoxic T lymphocyte-based tumour immunotherapy. Immunology (2015) 0.79
Transformation, translation and TRAIL: an unexpected intersection. Cytokine Growth Factor Rev (2008) 0.78
Pharmacokinetics of recombinant bifunctional fusion proteins. Expert Opin Drug Metab Toxicol (2012) 0.77
Synergistic interaction between selective drugs in cell populations models. PLoS One (2015) 0.75
Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products. Drugs (2015) 0.75